<DOC>
	<DOCNO>NCT01795859</DOCNO>
	<brief_summary>The purpose study determine whether SD-809 ER tablet effective treatment chorea associate Huntington 's Disease .</brief_summary>
	<brief_title>First Time Use SD-809 Huntington Disease</brief_title>
	<detailed_description>This randomize , double blind , placebo control , parallel group study design evaluate efficacy , safety tolerability SD-809 ER treatment chorea associate Huntington 's Disease . Approximately 90 subject randomize ( 1:1 ) study , approximately 45 subject receive SD-809 ER 45 subject receive placebo . The study conduct approximately 30 center U.S. Canada .</detailed_description>
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Chorea</mesh_term>
	<criteria>1 . Subject least 18 year age age majority ( whichever old ) Screening . 2 . Subject diagnosed manifest HD , indicate characteristic motor exam feature document expanded CAG repeat ( ≥ 37 ) Screening . 3 . Subject Total Maximal Chorea Score ( TMC ) ≥ 8 Screening Baseline . 4 . Subject Total Functional Capacity ( TFC ) score ≥ 5 Screening . 5 . Subject able swallow study medication whole . 6 . Subject provide write , informed consent , legally authorize representative ( LAR ) provide write informed consent subject provide assent . 7 . Female subject childbearing potential agree use acceptable method contraception screen study completion . 8 . The subject reliable caregiver interacts patient daily basis , oversee study drug administration , assure attendance study visit participates evaluation , require . 9 . Subject able ambulate without assistance least 20 yard ( Note : The use assistive device ( i.e. , walker , cane ) permit ambulation ) . 1 . Subject serious untreated undertreated psychiatric illness , depression , Screening Baseline . 2 . Subject active suicidal ideation Screening Baseline . 3 . Subject history suicidal behavior Screening Baseline : 4 . Subject evidence depression Screening Baseline . 5 . Subject unstable serious medical psychiatric illness Screening Baseline . 6 . Subject recently expose tetrabenazine . 7 . Subject receive follow concomitant medication within 30 day Screening Baseline : Antipsychotics Metoclopramide Monoamine oxidase inhibitor ( MAOI ) Levodopa dopamine agonist Reserpine Amantadine Memantine 8 . Subject significantly impaired swallow function Screening . 9 . Subject significantly impaired speak Screening . 10 . Subject require treatment drug know prolong QT interval . 11 . Subject prolonged QT interval 12lead ECG Screening . 12 . Subject evidence hepatic impairment Screening . 13 . Subject evidence significant renal impairment Screening . 14 . Subject know allergy component study medication . 15 . Subject participate investigational drug device trial within 30 day ( 5 drug halflives ) Screening , whichever longer . 16 . Subject pregnant breastfeeding Screening Baseline . 17 . Subject acknowledges present use illicit drug Screening . 18 . Subject history alcohol substance abuse previous 12 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Huntington disease</keyword>
	<keyword>Chorea</keyword>
	<keyword>Tetrabenazine</keyword>
</DOC>